Robin LaChapelle, Chief Operating Officer of ArriVent BioPharma, Inc., filed a Form 4 on November 2, 2026, reporting five stock option exercises transacted on October 30, 2026, resulting in acquisitions of Common Stock across multiple tranches.

Key Highlights

  • Five option exercises on October 30, 2026: LaChapelle exercised stock options covering 410, 4,550, 1,820, 16,265, and 17,648 shares of Common Stock, each coded "M" (exercise of in-the-money or at-the-money derivative).
  • Exercise prices vary by grant: Options were exercised at $2.2815, $3.6504, and $6.2361 per share, per the filing, reflecting a 15.21-for-1 reverse stock split adjustment applied at the January 23, 2024 IPO.
  • Direct beneficial ownership after transactions: Following all reported exercises, LaChapelle directly owns 176,429 shares of Common Stock.
  • Indirect ownership via trust: The filing also reports 394,477 shares held indirectly through The MAKS Yao Trust, of which LaChapelle is Trustee; the filing states LaChapelle "does not have a pecuniary interest in and disclaims beneficial ownership of the shares held by The MAKS Yao Trust."
  • Remaining derivative holdings: After the exercises, LaChapelle retains 0, 1,820, 0, 2,600, and 38,823 shares underlying the five respective stock option series, per Table II.
  • Filing made by attorney-in-fact: The form was signed by James Kastenmayer as Attorney-in-Fact for Robin LaChapelle on November 2, 2026.

Robin LaChapelle's October 2026 Option Exercises at ArriVent BioPharma

According to the Form 4 filed with the SEC on November 2, 2026, Robin LaChapelle, Chief Operating Officer of ArriVent BioPharma, Inc. (NASDAQ:AVBP), reported five separate stock option exercises, all dated October 30, 2026. The exercises were conducted under transaction code "M" and covered shares of Common Stock underlying options with exercise prices of $2.2815, $3.6504, and $6.2361, respectively. The filing notes that those per-share prices reflect a 15.21-for-1 reverse stock split effected on January 23, 2024, in connection with the issuer's initial public offering, under which the underlying share counts were divided by 15.21 and the exercise prices were multiplied by 15.21.

The five tranches acquired 410, 4,550, 1,820, 16,265, and 17,648 shares, bringing LaChapelle's direct beneficial ownership to 176,429 shares of Common Stock following all reported transactions. The filing additionally reports 394,477 shares held indirectly through The MAKS Yao Trust. LaChapelle is identified as Trustee of that trust and, per the filing, "may be deemed to have shared voting and investment power over the shares held by The MAKS Yao Trust," while expressly disclaiming beneficial ownership of and any pecuniary interest in those shares.

The vesting schedules disclosed in the filing show that each option series vested 25% on a specific date (ranging from September 8, 2022, through August 22, 2024), with the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service. After the October 30, 2026 exercises, residual option positions of 1,820 shares (expiring January 31, 2032), 2,600 shares (expiring January 31, 2033), and 38,823 shares (expiring August 21, 2033) remain directly held, according to Table II of the filing.

What Was Disclosed

LaChapelle's Form 4 discloses five stock option exercises by ArriVent BioPharma's COO on October 30, 2026, adding 40,693 shares directly, bringing total direct holdings to 176,429 shares, with 394,477 additional shares held indirectly through a trust in which she disclaims pecuniary interest.